Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow versus TOBI nebulized with PARI LC PLUS in subjects with CF.

Trial Profile

Randomized, open labelled, cross over deposition study of Tobramycin 100 PARI nebulized with eFlow versus TOBI nebulized with PARI LC PLUS in subjects with CF.

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Pseudomonal infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jul 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top